NEW YORK ( TheStreet) -- Clinical Data (Nasdaq: CLDA) is trading at unusually high volume Tuesday with 5.2 million shares changing hands. It is currently at 5.5 times its average daily volume and trading down $2.99 (-8.8%) at $30.91 as of 9:51 a.m. ET. Clinical Data has a market cap of $1 billion and is part of the health care sector and drugs industry. Shares are up 113.1% year to date as of the close of trading on Friday. Clinical Data, Inc. operates as a global biotechnology company developing early and late stage targeted therapeutics, as well as genetic and pharmacogenomic tests that detect serious diseases and help predict drug safety, tolerability, and efficacy. TheStreet Ratings rates Clinical Data as sell. Among the areas we feel are negative, one of the most important has been poor debt management on most measures. You can view the full Clinical Data Ratings Report. See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center.
Cheng Yi Liang, a chemist with the U.S. Food and Drug Administration, was charged by the Securities and Exchange Commission with insider trading on information regarding upcoming FDA drug approval decisions on Tuesday.